Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ezabenlimab - Boehringer Ingelheim

X
Drug Profile

Ezabenlimab - Boehringer Ingelheim

Alternative Names: BI-754091

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Amal Therapeutics; Boehringer Ingelheim; National Health Research Institutes
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anal cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Phase I/II Colorectal cancer
  • Phase I Adenocarcinoma; Liver cancer; Neuroendocrine tumours; Small cell lung cancer
  • No development reported Head and neck cancer; Non-small cell lung cancer

Most Recent Events

  • 22 Apr 2024 Boehringer Ingelheim plans a phase III Brightline-3 trial for Soft tissue sarcoma (Late-stage disease, Monotherapy, Combination therapy, Second-line therapy or greater) (PO), in June 2024 (NCT06370871)
  • 31 Jan 2024 Boehringer Ingelheim initiates enrolment in a phase I trial for Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Japan (NCT06091930) (IV)
  • 18 Jan 2024 Efficacy and adverse events data from the phase II INTERACT-ION trial in Anal cancer presented at the Gastrointestinal Cancers Symposium ASCO-GCS-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top